New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For TEVA;NVS From The Last 14 Days
Check below for free stories on TEVA;NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
14:04 EDTNVSWorldwide Business Research to hold a conference
Subscribe for More Information
13:47 EDTNVSNovartis heart failure drug LCZ696 shows superiority to enalapril in study
Subscribe for More Information
12:50 EDTNVSEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 29, 2014
16:21 EDTNVSOn The Fly: Closing Wrap
Subscribe for More Information
12:23 EDTNVSNovartis drug data to be presented this weekend
Subscribe for More Information
12:18 EDTNVSOn The Fly: Midday Wrap
Subscribe for More Information
11:07 EDTNVSHigh option volume stocks
Subscribe for More Information
10:51 EDTNVSUnited Therapeutics jumps after court rules generic will infringe
United Therapeutics (UTHR) alleged patent infringement against Sandoz, a unit of Novartis (NVS), related to the latter's filing for approval of a generic version of United Therapeutics' remodulin drug. A New Jersey court ruled today that Sandoz's proposed ANDA product will infringe the claims of UTC's '117 patent, according to a court filing. Following the court ruling, shares of United Therapeutics are up 15% to $105.39 in morning trading.
10:17 EDTNVSInnoPharma announces FDA approval of generic Dacogen
Subscribe for More Information
10:04 EDTNVSNovartis hematopoietic support for ALL patients granted orphan status
Novartis' hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor antagonist was granted orphan designation as a hematopoietic support in patients with acute lymphoblastic leukemia, or ALL, the FDA stated. Reference Link
08:46 EDTNVSNovartis has a conference call hosted by JPMorgan
JPMorgan Analyst Vosser hosts a conference call with CEO Joe Jimenez on September 5 at 8 am.
August 28, 2014
11:22 EDTTEVAMylan ANDA for three times per week generic Copaxone accepted by FDA for filing
Mylan (MYL) announced that its abbreviated new drug application for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted for filing by the U.S. Food and Drug Administration. This product is the generic version of Teva's (TEVA) Copaxone 40 mg/mL, which is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Mylan believes it is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and expects to be eligible for 180 days of marketing exclusivity in the U.S. upon final FDA approval. Copaxone 40 mg/mL had U.S. sales of approximately $411.5M for the 12 months ending June 30, 2014, according to IMS Health.
08:40 EDTNVSPositive data on Novartis LCZ696 could raise sales outlook, says Leerink
Subscribe for More Information
07:21 EDTTEVATeva recalls batch of generic Parkinson's drug in U.S., Globes reports
Subscribe for More Information
August 21, 2014
15:16 EDTTEVADEA restricts painkiller drug prescriptions to curb abuse, WSJ reports
The Drug Enforcement Agency, or DEA, will reclassify hydrocodone combination painkiller drugs and place them in the category of medical substances that have the highest potential for harm in an attempt to curb the widespread abuse of the drugs, according to The Wall Street Journal. The rescheduling of the drugs will take effect in 45 days and result in people being able to obtain the drug for only 90 days without obtaining a new prescription. Major manufacturers of these drugs include Teva Pharmaceutical (TEVA), Mallinckrodt (MNK), AbbVie (ABBV), and Actavis (ACT). Reference Link
August 20, 2014
12:06 EDTNVSNovartis treatment for pigmented villonodular synovitis gets orphan designation
According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
August 19, 2014
05:11 EDTTEVA, NVSGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use